ยาเคมีบำบัดสูตร Trastuzumab -

Trastuzumab exposure for a relatively short period does not seem to substantially affect the pregnancy outcome In contrast, a more prolonged

Interpretation We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2-positive early

trastuzumab trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery

trastuzumab Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal